#5679 PATIENT OUTCOME IN A SWEDISH SINGLE-CENTRE COHORT OF ANCA-ASSOCIATED VASCULITIS WITH RENAL INVOLVEMENT

Abstract Background and Aims End-stage kidney disease premature death are common in patients with antineutrophil cytoplasmic antibody (ANCA) -associated vasculitis (AAV) renal involvement. Poor patient outcome is attributed to multiple factors comprising a delay diagnosis treatment, inadequate efficacy of treatments, complications due toxic effects given immunosuppressive therapy. The aim the present study was evaluate clinical prognostic features Swedish cohort AAV investigate pattern treatment predictors survival. Method Ninety-one diagnosed involvement between 01 March 2002 30 October 2018 single-centre were included retrospective study. Results Among these ninety-one patients, 52 (57%) PR3-ANCA, 39 (43%) MPO-ANCA. Patients PR3-ANCA MPO-ANCA received comparable induction However, frequency PLEX significantly higher versus (44% vs. 21% respectively; P = 0.025). Overall survival at 1- 5-year 91% 69% respectively no significant differences Overall, 1-year 92% 77% respectively. overall time mean was11.5 years 95% confidence interval (CI) 9.9 13.0 years. Mean 10.8; CI 8.8 12.7 11.7; 9.6 13.8 those PR3-ANCA. Cox regression analysis showed that advancing age predicted mortality risk, whereas subtype lower risk (Figure 1). Infection (25%), malignancy (22%), cardiovascular events (16%) major causes cohort. In subgroup thirty-two eGFR <15 ml/min per 1.73 m2 or undergoing dialysis diagnosis. Twenty-three (72%) treated PLEX, 9 (28%) did not receive as part remission Treatment had on Conclusion this high. Advancing while risk. severe AAV.